Listed below are the Topics in Antiviral Medicine Editorial Board members and their financial relationships with ineligible companies within the past 24 months from the date of disclosure. Members of the TAM Editorial Board are compensated for their work on the journal.
The ACCME defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
Editor in Chief
Douglas D. Richman, MD
Professor of Pathology and Medicine
University of California San Diego
La Jolla, California
Dr Richman reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated July 23, 2025)
Members
Constance A. Benson, MD
Professor of Medicine
University of California San Diego
San Diego, California
Dr Benson reported receiving fees for participation in review activities, eg, data monitoring boards, statistical analysis, or endpoint adjudication committees from ViiV Healthcare: and consulting or advisor fees from Antiva. (Updated July 9, 2025)
Martin S. Hirsch, MD
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Dr Hirsch reported no relevant financial relationships with ineligible companies. (Updated August 7, 2025)